Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HK1 | P19367 | 1/20 | 0.41 |
| ▸ | GALK1 | P51570 | 1/20 | 0.41 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 4/20 | 0.38 |
| ▸ | SRC | P12931 | 2/20 | 0.38 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.38 |
| ▸ | AHR | P35869 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9302961 | 0.80 | MAPT (0.40) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL1042744 | 0.79 | MAPT (0.41) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL28746696 | 0.79 | MAPT (0.39) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL9303152 | 0.76 | MAPT (0.39) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL6571089 | 0.75 | ALDH1A1 (0.36) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL29420631 | 0.74 | GSK3A (0.39) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL31087892 | 0.72 | CDK2 (0.34) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL1120300 | 0.71 | MAPT (0.40) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL29352286 | 0.71 | MAPT (0.40) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL21316073 | 0.71 | MEN1 (0.63) | MEN1KMT2AMAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355881-A4 | AN IMPROVED PROCESS FOR PREPARING PURE ONDANSETRON HYDROCHLORIDE DIHYDRATE | TEVA PHARMA (IL) | 2004-03-31 | — | — | EP | claimed |
| EP-1355881-A2 | AN IMPROVED PROCESS FOR PREPARING PURE ONDANSETRON HYDROCHLORIDE DIHYDRATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-10-29 | — | — | EP | claimed |
| US-20020115707-A1 | Process for preparing pure ondansetron hydrochloride dihydrate | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-08-22 | — | — | US | claimed |
| WO-2002055492-A2 | AN IMPROVED PROCESS FOR PREPARING PURE ONDANSETRON HYDROCHLORIDE DIHYDRATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-07-18 | — | — | WO | claimed |
| EP-1355881-A4 | AN IMPROVED PROCESS FOR PREPARING PURE ONDANSETRON HYDROCHLORIDE DIHYDRATE | TEVA PHARMA (IL) | 2004-03-31 | — | — | EP | disclosed |
| EP-1355881-A2 | AN IMPROVED PROCESS FOR PREPARING PURE ONDANSETRON HYDROCHLORIDE DIHYDRATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-10-29 | — | — | EP | disclosed |
| US-20020115707-A1 | Process for preparing pure ondansetron hydrochloride dihydrate | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-08-22 | — | — | US | disclosed |
| WO-2002055492-A2 | AN IMPROVED PROCESS FOR PREPARING PURE ONDANSETRON HYDROCHLORIDE DIHYDRATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-07-18 | — | — | WO | disclosed |
| WO-1994009002-A1 | 2-(AZA-9-FLUORENONYL)CARBAPENEM ANTIBACTERIAL AGENTS | MERCK & CO., INC. (US) | 1994-04-28 | — | — | WO | disclosed |
| US-5294610-A | Staphylococcus; side effect reduction | MERCK & CO. INC. (US) | 1994-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115707-A1 | Process for preparing pure ondansetron hydrochloride dihydrate | HTR4, DRD4, MLN | MEN1 1830/4885KMT2A 1033/4885MAPT 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.